{"success":true,"data":{"pressRelease":{"id":"146340","rtpr_id":"nBwtq8ssa-20260917","ticker":"LTRN","exchange":"NASDAQ","all_tickers":["LTRN"],"title":"Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23","author":"Business Wire","published_at":"2026-09-17T12:20:00.130Z","article_body":"Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for\nEnd-to-End Therapeutic Development — Business Model, Roadmap, and Value\nProposition on September 23\n\n\n * Built Inside Active Clinical Programs: A New Generation of AI Co-Scientists\nDesigned to Compress Research Timelines and Expand What Is Possible in Drug\nDevelopment\n\n * Open-Medicine AI Founder & CEO Panna Sharma to Detail How Open-Medicine AI\nIs Evolving Beyond Rare Cancers to Target Additional Disease Categories, New\nModalities, and Critical Downstream Real-World Drug Development Challenges\n\n * Webinar to Be Held Wednesday, September 23, 2026 at 12:30 PM Eastern / 9:30 AM\nPacific — \nRegister Here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fus06web.zoom.us%2Fwebinar%2Fregister%2F9417895172347%2FWN_HNnjzsDuTjufesN-cdwaNw%23%2Fregistration&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=Register+Here&index=1&md5=10fd9d6d98a7f125f9eaea29385e1b57)\n\nLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma\ncompany using artificial intelligence and genomic data to develop precision\noncology therapies, today announced that it will host a live webinar on\nWednesday, September 23, 2026 at 12:30 PM Eastern to present the business\nmodel, development roadmap, and value proposition of Open-Medicine AI (OMAI),\nthe company’s wholly owned subsidiary building a multi-agentic AI platform\nfor end-to-end therapeutic development.\n\nPanna Sharma, Founder and CEO of Open-Medicine AI, will lead the session,\nwhich is intended for investors, biopharma and academic collaborators, and\nprospective partners. The webinar will explain how OMAI is extending the AI\nco-scientist approach first commercialized in withZeta.ai — launched in\nApril 2026 and focused on rare and aggressive cancers — into additional\ndisease categories, new therapeutic modalities, and the downstream development\nchallenges that consume most of the time and cost between a validated target\nand a treated patient. A question-and-answer period will follow the\npresentation.\n\nBuilt Where the Problems Are\n\nMost AI for drug discovery is built at a distance from drug development.\nOpen-Medicine AI was built inside it. Its co-scientists were developed within\nLantern’s own clinical programs — with the same data, constraints,\nregulatory requirements, and decision points that determine whether a molecule\nreaches patients — and were first put to work in withZeta.ai, which launched\nin April 2026 and is in use across rare and aggressive cancers.\n\nThe drug discovery and development markets are already moving in this\ndirection. Independent analysts estimate the AI in drug discovery market at\napproximately $2.9 billion in 2026, growing to $13.8 billion by 2033.(1)\nAdditionally, analysts have noted that AI deployments in pharma are moving\nfrom pilots to enterprise-scale, agentic systems.(2, 3)\n\nThe result is a platform that does more than propose candidates. It reasons\nacross the full development pathway — target and biomarker selection,\ncompound and modality design, translational analysis, trial design, and\nregulatory strategy — in which the agents carry the operating knowledge of\nthe scientists and clinicians who built them. The webinar will present:\n\n\n * The platform: the multi-agentic architecture behind Open-Medicine AI, how its\nco-scientists coordinate across the development pathway, and what\ndistinguishes an agent trained inside active clinical programs from a\ngeneral-purpose model\n\n * The roadmap: the next generation of co-scientists beyond rare cancers, the\ndisease categories and therapeutic modalities being prioritized, and the\ndownstream development challenges — trial design, patient selection,\nregulatory and translational work — that the platform is being extended to\naddress\n\n * The business model: how Open-Medicine AI intends to generate revenue through\nsubscription access and enterprise licensing, and how it works with biopharma\ncompanies, research institutions, service providers, and drug developers\n\n * The value proposition: where the platform is designed to remove time, cost,\nand failure from the path between a validated target and a treated patient,\nand how that is measured\n\n * Why now: why an AI platform for therapeutic development is best built by a\ncompany that develops therapeutics, and what that means for Lantern Pharma\nshareholders and for the researchers, developers, and technology partners who\nwill use it\n\n“We did not set out to build an AI company. We set out to get cancer drugs\nto patients faster and with less capital, and we built the tools we needed to\ndo that because they did not exist. withZeta.ai is what came out of that work,\nand it is now running inside real programs with real regulatory and clinical\nconsequences. Open-Medicine AI takes that architecture beyond rare cancers and\nbeyond Lantern — into new disease categories, new modalities, and the\ndownstream parts of development where most of the time, cost, and failure\nlive. On September 23 we will show what we have built, how it will be adopted\nby industry professionals and service providers, and what the development\nroadmap for the platform and business could look like. We believe that the\nmost useful AI for therapeutic development will come from the people who have\nactually developed therapeutics and taken them into meaningful trials for the\nbenefit of patients, and done so with a data-driven, time- and cost-conscious\nmentality.”\n\n— Panna Sharma, President and Chief Executive Officer, Lantern Pharma\n\nWebinar Details\n Title         Open-Medicine AI: A Multi-Agentic Platform for End-to-End Therapeutic                                                                                                                                                                                                                                                                                                                                                         \n               Development — Business Model, Roadmap, and Value Proposition                                                                                                                                                                                                                                                                                                                                                                  \n Date          Wednesday, September 23, 2026                                                                                                                                                                                                                                                                                                                                                                                                 \n Time          12:30 PM Eastern / 9:30 AM Pacific                                                                                                                                                                                                                                                                                                                                                                                            \n Presenter     Panna Sharma, President and CEO, Lantern Pharma; Founder and CEO,                                                                                                                                                                                                                                                                                                                                                             \n               Open-Medicine AI                                                                                                                                                                                                                                                                                                                                                                                                              \n Format        45 minutes — a 30–35 minute presentation followed by live Q&A;                                                                                                                                                                                                                                                                                                                                                            \n               questions may be submitted in advance to IR@lanternpharma.com                                                                                                                                                                                                                                                                                                                                                                 \n               (mailto:IR@lanternpharma.com)                                                                                                                                                                                                                                                                                                                                                                                                 \n Registration  https://us06web.zoom.us/webinar/register/9417895172347/WN_HNnjzsDuTjufesN-cdwaNw#/registration                                                                                                                                                                                                                                                                                                                                \n               (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fus06web.zoom.us%2Fwebinar%2Fregister%2F9417895172347%2FWN_HNnjzsDuTjufesN-cdwaNw%23%2Fregistration&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=https%3A%2F%2Fus06web.zoom.us%2Fwebinar%2Fregister%2F9417895172347%2FWN_HNnjzsDuTjufesN-cdwaNw%23%2Fregistration&index=2&md5=18fd8798faee20da48c1b96a1d422f83)                               \n Replay        A recording will be available on the Investors section of                                                                                                                                                                                                                                                                                                                                                                     \n               www.lanternpharma.com                                                                                                                                                                                                                                                                                                                                                                                                         \n               (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.lanternpharma.com&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=www.lanternpharma.com&index=3&md5=579f29a6d88909cc0d69053b87583955)                                                                                                                                                                                                        \n               following the event                                                                                                                                                                                                                                                                                                                                                                                                           \n\n\nAbout Open-Medicine AI\n\nOpen-Medicine AI (OMAI) is a wholly owned subsidiary of Lantern Pharma\nbuilding a multi-agentic AI platform for end-to-end therapeutic development.\nIts AI co-scientists were developed inside Lantern’s clinical-stage oncology\nprograms and carry the data, constraints, and decision points of real drug\ndevelopment — from target and biomarker selection through compound design,\ntranslational analysis, trial design, and regulatory strategy. The platform\nwas first commercialized as withZeta.ai, launched in April 2026 for rare and\naggressive cancers, and expanded in July 2026 with ZetaOmics™, a\ncomputational biology module released to early-access users. OMAI is extending\nthis architecture to additional disease categories, new therapeutic\nmodalities, and the downstream challenges of drug development. The platform is\navailable to biopharma companies, research institutions, service providers,\nand drug developers through subscription and enterprise licensing. For more\ninformation, visit www.open-medicine.ai\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.open-medicine.ai&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=www.open-medicine.ai&index=4&md5=6dc437e07b7589fb3d45defc10002a9c)\n.\n\nAbout Lantern Pharma\n\nLantern Pharma (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company\nleveraging its proprietary RADR® artificial intelligence and machine-learning\nplatform to transform the cost, pace, and precision of oncology drug\ndevelopment. By integrating large-scale genomic and biological data with\nadvanced machine learning, RADR® is designed to identify the patients most\nlikely to benefit from Lantern’s therapies and to guide biomarker-driven\nclinical development. The company’s pipeline includes LP-184 (zirdafulven),\nLP-300, and LP-284, along with its central-nervous-system-focused subsidiary,\nStarlight Therapeutics, and its AI subsidiary, Open-Medicine AI. For more\ninformation, visit www.lanternpharma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.lanternpharma.com&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=www.lanternpharma.com&index=5&md5=d977161d0c507e84b0b4b5d190a6c43a)\n.\n\nSelected References\n\n1. Grand View Research. Artificial Intelligence in Drug Discovery Market Size,\nShare & Trends Analysis Report, 2026–2033. Available at:\ngrandviewresearch.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fgrandviewresearch.com&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=grandviewresearch.com&index=6&md5=fefc93db93948bec1c069cf09de73c12)\n.\n\n2. IntuitionLabs. Big Pharma & Hyperscaler AI Deals: 2026 Industry\nTracker. 2026. Available at: intuitionlabs.ai\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fintuitionlabs.ai&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=intuitionlabs.ai&index=7&md5=9fe7c5b18fd8a15ab80e3eb04a6ecdf1)\n.\n\n3. Securities.io - AI Drug Discovery Is Triggering a Biotech M&A\nSupercycle – Available at\nhttps://www.securities.io/ai-drug-discovery-biotech-ma-supercycle-2026/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.securities.io%2Fai-drug-discovery-biotech-ma-supercycle-2026%2F&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=https%3A%2F%2Fwww.securities.io%2Fai-drug-discovery-biotech-ma-supercycle-2026%2F&index=8&md5=89660393f88cea7c90baffcad0512ebc)\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. These forward-looking statements\ninclude, among other things, statements relating to: future events or our\nfuture financial performance; the market opportunity, platform roadmap, and\ncommercial model for the Open-Medicine AI platform; the planned evolution of\nthe Open-Medicine AI platform beyond withZeta.ai to target broader disease\nareas, new modalities, and additional real-world drug development challenges;\nthe planned development, value proposition and commercial potential of the\nOpen-Medicine AI platform, including our plans to compress research timelines\nand expand what is possible in drug development; and the potential advantages\nof the Open Medicine AI platform in identifying drug candidates, accelerating\ndrug development, and generating revenue through software licensing and\nsubscription models.\n\nAny statements that are not statements of historical fact (including, without\nlimitation, statements that use words such as “anticipate,” “believe,”\n“contemplate,” “could,” “estimate,” “expect,” “intend,”\n“seek,” “may,” “might,” “plan,” “potential,”\n“predict,” “project,” “target,” “model,” “objective,”\n“aim,” “upcoming,” “should,” “will,” “would,” or the\nnegative of these words or other similar expressions) should be considered\nforward-looking statements. There are a number of important factors that could\ncause our actual results to differ materially from those indicated by the\nforward-looking statements, such as (i) the risk that we may not be able to\nsecure sufficient future funding when needed and as required to advance and\nsupport our existing and planned development programs and operations, (ii) the\nrisk that our Open-Medicine AI commercialization efforts may not generate the\nanticipated revenue or achieve the expected market adoption, (iii) the risk\nthat implementation of our development plans and new features for\nOpen-Medicine AI may not be successful or may take longer than anticipated for\ndevelopment, completion, and release, (iv) the risk that no drug product based\non our proprietary AI platforms has received FDA marketing approval or\notherwise been incorporated into a commercial product, and (v) technical,\nscientific, regulatory, financial, competitive, and operational risks and\nthose other factors set forth in the Risk Factors section in our Annual Report\non Form 10-K for the year ended December 31, 2025, filed with the Securities\nand Exchange Commission on March 30, 2026.\n\nYou may access our Annual Report on Form 10-K for the year ended December 31,\n2025 under the investor SEC filings tab of our website at\nwww.lanternpharma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.lanternpharma.com&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=www.lanternpharma.com&index=9&md5=ef55f3bd97b0efa30bd0e9183b4b54cf)\nor on the SEC’s website at www.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.sec.gov&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=www.sec.gov&index=10&md5=23446f55abf1eee0e6df48b002ed35af)\n. Given these risks and uncertainties, we can give no assurances that our\nforward-looking statements will prove to be accurate, or that any other\nresults or events projected or contemplated by our forward-looking statements\nwill in fact occur, and we caution investors not to place undue reliance on\nthese statements. All forward-looking statements in this press release\nrepresent our judgment as of the date hereof, and, except as otherwise\nrequired by law, we disclaim any obligation to update any forward-looking\nstatements to conform the statement to actual results or changes in our\nexpectations.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260917913329/en/\n(https://www.businesswire.com/news/home/20260917913329/en/)\n\nMedia & Investor Contacts \n\nLantern Pharma — Investor Relations\n\nEmail: IR@lanternpharma.com \n(mailto:IR@lanternpharma.com) \nPhone: (972) 277-1136\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBwtq8ssa-20260917","title":"Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23","author":"Business Wire","ticker":"LTRN","created":"2026-09-17T12:20:00.130Z","tickers":["LTRN"],"exchange":"NASDAQ","article_body":"Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for\nEnd-to-End Therapeutic Development — Business Model, Roadmap, and Value\nProposition on September 23\n\n\n * Built Inside Active Clinical Programs: A New Generation of AI Co-Scientists\nDesigned to Compress Research Timelines and Expand What Is Possible in Drug\nDevelopment\n\n * Open-Medicine AI Founder & CEO Panna Sharma to Detail How Open-Medicine AI\nIs Evolving Beyond Rare Cancers to Target Additional Disease Categories, New\nModalities, and Critical Downstream Real-World Drug Development Challenges\n\n * Webinar to Be Held Wednesday, September 23, 2026 at 12:30 PM Eastern / 9:30 AM\nPacific — \nRegister Here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fus06web.zoom.us%2Fwebinar%2Fregister%2F9417895172347%2FWN_HNnjzsDuTjufesN-cdwaNw%23%2Fregistration&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=Register+Here&index=1&md5=10fd9d6d98a7f125f9eaea29385e1b57)\n\nLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma\ncompany using artificial intelligence and genomic data to develop precision\noncology therapies, today announced that it will host a live webinar on\nWednesday, September 23, 2026 at 12:30 PM Eastern to present the business\nmodel, development roadmap, and value proposition of Open-Medicine AI (OMAI),\nthe company’s wholly owned subsidiary building a multi-agentic AI platform\nfor end-to-end therapeutic development.\n\nPanna Sharma, Founder and CEO of Open-Medicine AI, will lead the session,\nwhich is intended for investors, biopharma and academic collaborators, and\nprospective partners. The webinar will explain how OMAI is extending the AI\nco-scientist approach first commercialized in withZeta.ai — launched in\nApril 2026 and focused on rare and aggressive cancers — into additional\ndisease categories, new therapeutic modalities, and the downstream development\nchallenges that consume most of the time and cost between a validated target\nand a treated patient. A question-and-answer period will follow the\npresentation.\n\nBuilt Where the Problems Are\n\nMost AI for drug discovery is built at a distance from drug development.\nOpen-Medicine AI was built inside it. Its co-scientists were developed within\nLantern’s own clinical programs — with the same data, constraints,\nregulatory requirements, and decision points that determine whether a molecule\nreaches patients — and were first put to work in withZeta.ai, which launched\nin April 2026 and is in use across rare and aggressive cancers.\n\nThe drug discovery and development markets are already moving in this\ndirection. Independent analysts estimate the AI in drug discovery market at\napproximately $2.9 billion in 2026, growing to $13.8 billion by 2033.(1)\nAdditionally, analysts have noted that AI deployments in pharma are moving\nfrom pilots to enterprise-scale, agentic systems.(2, 3)\n\nThe result is a platform that does more than propose candidates. It reasons\nacross the full development pathway — target and biomarker selection,\ncompound and modality design, translational analysis, trial design, and\nregulatory strategy — in which the agents carry the operating knowledge of\nthe scientists and clinicians who built them. The webinar will present:\n\n\n * The platform: the multi-agentic architecture behind Open-Medicine AI, how its\nco-scientists coordinate across the development pathway, and what\ndistinguishes an agent trained inside active clinical programs from a\ngeneral-purpose model\n\n * The roadmap: the next generation of co-scientists beyond rare cancers, the\ndisease categories and therapeutic modalities being prioritized, and the\ndownstream development challenges — trial design, patient selection,\nregulatory and translational work — that the platform is being extended to\naddress\n\n * The business model: how Open-Medicine AI intends to generate revenue through\nsubscription access and enterprise licensing, and how it works with biopharma\ncompanies, research institutions, service providers, and drug developers\n\n * The value proposition: where the platform is designed to remove time, cost,\nand failure from the path between a validated target and a treated patient,\nand how that is measured\n\n * Why now: why an AI platform for therapeutic development is best built by a\ncompany that develops therapeutics, and what that means for Lantern Pharma\nshareholders and for the researchers, developers, and technology partners who\nwill use it\n\n“We did not set out to build an AI company. We set out to get cancer drugs\nto patients faster and with less capital, and we built the tools we needed to\ndo that because they did not exist. withZeta.ai is what came out of that work,\nand it is now running inside real programs with real regulatory and clinical\nconsequences. Open-Medicine AI takes that architecture beyond rare cancers and\nbeyond Lantern — into new disease categories, new modalities, and the\ndownstream parts of development where most of the time, cost, and failure\nlive. On September 23 we will show what we have built, how it will be adopted\nby industry professionals and service providers, and what the development\nroadmap for the platform and business could look like. We believe that the\nmost useful AI for therapeutic development will come from the people who have\nactually developed therapeutics and taken them into meaningful trials for the\nbenefit of patients, and done so with a data-driven, time- and cost-conscious\nmentality.”\n\n— Panna Sharma, President and Chief Executive Officer, Lantern Pharma\n\nWebinar Details\n Title         Open-Medicine AI: A Multi-Agentic Platform for End-to-End Therapeutic                                                                                                                                                                                                                                                                                                                                                         \n               Development — Business Model, Roadmap, and Value Proposition                                                                                                                                                                                                                                                                                                                                                                  \n Date          Wednesday, September 23, 2026                                                                                                                                                                                                                                                                                                                                                                                                 \n Time          12:30 PM Eastern / 9:30 AM Pacific                                                                                                                                                                                                                                                                                                                                                                                            \n Presenter     Panna Sharma, President and CEO, Lantern Pharma; Founder and CEO,                                                                                                                                                                                                                                                                                                                                                             \n               Open-Medicine AI                                                                                                                                                                                                                                                                                                                                                                                                              \n Format        45 minutes — a 30–35 minute presentation followed by live Q&A;                                                                                                                                                                                                                                                                                                                                                            \n               questions may be submitted in advance to IR@lanternpharma.com                                                                                                                                                                                                                                                                                                                                                                 \n               (mailto:IR@lanternpharma.com)                                                                                                                                                                                                                                                                                                                                                                                                 \n Registration  https://us06web.zoom.us/webinar/register/9417895172347/WN_HNnjzsDuTjufesN-cdwaNw#/registration                                                                                                                                                                                                                                                                                                                                \n               (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fus06web.zoom.us%2Fwebinar%2Fregister%2F9417895172347%2FWN_HNnjzsDuTjufesN-cdwaNw%23%2Fregistration&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=https%3A%2F%2Fus06web.zoom.us%2Fwebinar%2Fregister%2F9417895172347%2FWN_HNnjzsDuTjufesN-cdwaNw%23%2Fregistration&index=2&md5=18fd8798faee20da48c1b96a1d422f83)                               \n Replay        A recording will be available on the Investors section of                                                                                                                                                                                                                                                                                                                                                                     \n               www.lanternpharma.com                                                                                                                                                                                                                                                                                                                                                                                                         \n               (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.lanternpharma.com&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=www.lanternpharma.com&index=3&md5=579f29a6d88909cc0d69053b87583955)                                                                                                                                                                                                        \n               following the event                                                                                                                                                                                                                                                                                                                                                                                                           \n\n\nAbout Open-Medicine AI\n\nOpen-Medicine AI (OMAI) is a wholly owned subsidiary of Lantern Pharma\nbuilding a multi-agentic AI platform for end-to-end therapeutic development.\nIts AI co-scientists were developed inside Lantern’s clinical-stage oncology\nprograms and carry the data, constraints, and decision points of real drug\ndevelopment — from target and biomarker selection through compound design,\ntranslational analysis, trial design, and regulatory strategy. The platform\nwas first commercialized as withZeta.ai, launched in April 2026 for rare and\naggressive cancers, and expanded in July 2026 with ZetaOmics™, a\ncomputational biology module released to early-access users. OMAI is extending\nthis architecture to additional disease categories, new therapeutic\nmodalities, and the downstream challenges of drug development. The platform is\navailable to biopharma companies, research institutions, service providers,\nand drug developers through subscription and enterprise licensing. For more\ninformation, visit www.open-medicine.ai\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.open-medicine.ai&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=www.open-medicine.ai&index=4&md5=6dc437e07b7589fb3d45defc10002a9c)\n.\n\nAbout Lantern Pharma\n\nLantern Pharma (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company\nleveraging its proprietary RADR® artificial intelligence and machine-learning\nplatform to transform the cost, pace, and precision of oncology drug\ndevelopment. By integrating large-scale genomic and biological data with\nadvanced machine learning, RADR® is designed to identify the patients most\nlikely to benefit from Lantern’s therapies and to guide biomarker-driven\nclinical development. The company’s pipeline includes LP-184 (zirdafulven),\nLP-300, and LP-284, along with its central-nervous-system-focused subsidiary,\nStarlight Therapeutics, and its AI subsidiary, Open-Medicine AI. For more\ninformation, visit www.lanternpharma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.lanternpharma.com&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=www.lanternpharma.com&index=5&md5=d977161d0c507e84b0b4b5d190a6c43a)\n.\n\nSelected References\n\n1. Grand View Research. Artificial Intelligence in Drug Discovery Market Size,\nShare & Trends Analysis Report, 2026–2033. Available at:\ngrandviewresearch.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fgrandviewresearch.com&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=grandviewresearch.com&index=6&md5=fefc93db93948bec1c069cf09de73c12)\n.\n\n2. IntuitionLabs. Big Pharma & Hyperscaler AI Deals: 2026 Industry\nTracker. 2026. Available at: intuitionlabs.ai\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fintuitionlabs.ai&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=intuitionlabs.ai&index=7&md5=9fe7c5b18fd8a15ab80e3eb04a6ecdf1)\n.\n\n3. Securities.io - AI Drug Discovery Is Triggering a Biotech M&A\nSupercycle – Available at\nhttps://www.securities.io/ai-drug-discovery-biotech-ma-supercycle-2026/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.securities.io%2Fai-drug-discovery-biotech-ma-supercycle-2026%2F&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=https%3A%2F%2Fwww.securities.io%2Fai-drug-discovery-biotech-ma-supercycle-2026%2F&index=8&md5=89660393f88cea7c90baffcad0512ebc)\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. These forward-looking statements\ninclude, among other things, statements relating to: future events or our\nfuture financial performance; the market opportunity, platform roadmap, and\ncommercial model for the Open-Medicine AI platform; the planned evolution of\nthe Open-Medicine AI platform beyond withZeta.ai to target broader disease\nareas, new modalities, and additional real-world drug development challenges;\nthe planned development, value proposition and commercial potential of the\nOpen-Medicine AI platform, including our plans to compress research timelines\nand expand what is possible in drug development; and the potential advantages\nof the Open Medicine AI platform in identifying drug candidates, accelerating\ndrug development, and generating revenue through software licensing and\nsubscription models.\n\nAny statements that are not statements of historical fact (including, without\nlimitation, statements that use words such as “anticipate,” “believe,”\n“contemplate,” “could,” “estimate,” “expect,” “intend,”\n“seek,” “may,” “might,” “plan,” “potential,”\n“predict,” “project,” “target,” “model,” “objective,”\n“aim,” “upcoming,” “should,” “will,” “would,” or the\nnegative of these words or other similar expressions) should be considered\nforward-looking statements. There are a number of important factors that could\ncause our actual results to differ materially from those indicated by the\nforward-looking statements, such as (i) the risk that we may not be able to\nsecure sufficient future funding when needed and as required to advance and\nsupport our existing and planned development programs and operations, (ii) the\nrisk that our Open-Medicine AI commercialization efforts may not generate the\nanticipated revenue or achieve the expected market adoption, (iii) the risk\nthat implementation of our development plans and new features for\nOpen-Medicine AI may not be successful or may take longer than anticipated for\ndevelopment, completion, and release, (iv) the risk that no drug product based\non our proprietary AI platforms has received FDA marketing approval or\notherwise been incorporated into a commercial product, and (v) technical,\nscientific, regulatory, financial, competitive, and operational risks and\nthose other factors set forth in the Risk Factors section in our Annual Report\non Form 10-K for the year ended December 31, 2025, filed with the Securities\nand Exchange Commission on March 30, 2026.\n\nYou may access our Annual Report on Form 10-K for the year ended December 31,\n2025 under the investor SEC filings tab of our website at\nwww.lanternpharma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.lanternpharma.com&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=www.lanternpharma.com&index=9&md5=ef55f3bd97b0efa30bd0e9183b4b54cf)\nor on the SEC’s website at www.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.sec.gov&esheet=54606095&newsitemid=20260917913329&lan=en-US&anchor=www.sec.gov&index=10&md5=23446f55abf1eee0e6df48b002ed35af)\n. Given these risks and uncertainties, we can give no assurances that our\nforward-looking statements will prove to be accurate, or that any other\nresults or events projected or contemplated by our forward-looking statements\nwill in fact occur, and we caution investors not to place undue reliance on\nthese statements. All forward-looking statements in this press release\nrepresent our judgment as of the date hereof, and, except as otherwise\nrequired by law, we disclaim any obligation to update any forward-looking\nstatements to conform the statement to actual results or changes in our\nexpectations.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260917913329/en/\n(https://www.businesswire.com/news/home/20260917913329/en/)\n\nMedia & Investor Contacts \n\nLantern Pharma — Investor Relations\n\nEmail: IR@lanternpharma.com \n(mailto:IR@lanternpharma.com) \nPhone: (972) 277-1136\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-17T12:20:00.194740279Z","server_sent_at_ms":1789647600194},"received_at":"2026-09-17T12:20:00.312Z","source_url":"https://www.businesswire.com/news/home/20260917913329/en/"},"analysis":{"id":"135171","press_release_id":"146340","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["No new clinical data, revenue figures, or signed licensing/subscription deals disclosed — all commercial claims are forward-looking","Forward-looking statements section explicitly flags risk that Open-Medicine AI commercialization may not generate anticipated revenue or achieve market adoption","Company notes no drug product based on its proprietary AI platforms has received FDA marketing approval"],"eventType":"operations_update","narrative":"Lantern Pharma will host a live webinar on September 23, 2026 to present the business model, development roadmap, and value proposition of Open-Medicine AI, its wholly owned subsidiary building a multi-agentic AI platform for end-to-end therapeutic development.\n\nThe platform was first commercialized as withZeta.ai, launched in April 2026 for rare and aggressive cancers, and expanded in July 2026 with the ZetaOmics computational biology module; the webinar will outline a subscription and enterprise-licensing revenue model and expansion into new disease categories, modalities, and downstream development challenges.\n\nCEO Panna Sharma, who founded Open-Medicine AI, framed the tools as built inside Lantern's own clinical programs, citing analyst estimates that put the AI-in-drug-discovery market at roughly $2.9 billion in 2026, growing to $13.8 billion by 2033.\n\nNo new clinical data, financial results, or partnership terms were disclosed; the release is investor and partner marketing ahead of the presentation.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Lantern pitching its AI subsidiary's subscription/licensing monetization story — watch the Sept 23 webinar for concrete licensing deals or pricing that validate the software revenue narrative."},"keyFigures":{"customDimensions":{"webinar_date":"September 23, 2026","webinar_format":"45 minutes (30-35 minute presentation plus live Q&A)","zetaomics_release":"July 2026","withzeta_ai_launch":"April 2026","ai_drug_discovery_market_2026":"$2.9 billion","ai_drug_discovery_market_2033":"$13.8 billion"}},"quotedText":"We did not set out to build an AI company.","namedEntities":{"people":[{"name":"Panna Sharma","role":"President and CEO of Lantern Pharma; Founder and CEO of Open-Medicine AI"}],"products":["Open-Medicine AI (OMAI) platform","withZeta.ai","ZetaOmics","RADR","LP-184 (zirdafulven)","LP-300","LP-284"],"companies":[{"name":"Lantern Pharma Inc.","ticker":"LTRN","relationship":"filer"},{"name":"Open-Medicine AI","relationship":"wholly owned subsidiary"},{"name":"Starlight Therapeutics","relationship":"CNS-focused subsidiary"},{"name":"Grand View Research","relationship":"market research source"},{"name":"IntuitionLabs","relationship":"industry tracker source"},{"name":"Securities.io","relationship":"media source"}],"dollarAmounts":[{"amount":"$2.9 billion","context":"estimated AI in drug discovery market in 2026 (analyst estimate)"},{"amount":"$13.8 billion","context":"projected AI in drug discovery market by 2033"}]},"materialImpact":{"score":2,"reasoning":"This is an issuer-authored announcement of an upcoming investor webinar outlining the business model and roadmap of subsidiary Open-Medicine AI. No new clinical data, financial results, revenue, or partnership terms were disclosed, so it is promotional rather than a hard catalyst, but the subscription/licensing monetization plan and expansion beyond rare cancers are new strategic detail for investors."},"tickerRelevance":{"others":[],"primary":"LTRN"},"globalImportance":12,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"promotional-webinar-announcement","issuerAuthored":true,"commercialSubstance":"none-new-strategy-detail-only","retailNarrativeBoost":"AI drug discovery angle gives modest retail appeal"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Lantern Pharma will host a live webinar on September 23, 2026 to present the business model, development roadmap, and value proposition of Open-Medicine AI, its wholly owned subsidiary building a multi-agentic AI platform for end-to-end therapeutic development.\n\nThe platform was first commercialized as withZeta.ai, launched in April 2026 for rare and aggressive cancers, and expanded in July 2026 with the ZetaOmics computational biology module; the webinar will outline a subscription and enterprise-licensing revenue model and expansion into new disease categories, modalities, and downstream development challenges.\n\nCEO Panna Sharma, who founded Open-Medicine AI, framed the tools as built inside Lantern's own clinical programs, citing analyst estimates that put the AI-in-drug-discovery market at roughly $2.9 billion in 2026, growing to $13.8 billion by 2033.\n\nNo new clinical data, financial results, or partnership terms were disclosed; the release is investor and partner marketing ahead of the presentation.","key_figures":{"customDimensions":{"webinar_date":"September 23, 2026","webinar_format":"45 minutes (30-35 minute presentation plus live Q&A)","zetaomics_release":"July 2026","withzeta_ai_launch":"April 2026","ai_drug_discovery_market_2026":"$2.9 billion","ai_drug_discovery_market_2033":"$13.8 billion"}},"named_entities":{"people":[{"name":"Panna Sharma","role":"President and CEO of Lantern Pharma; Founder and CEO of Open-Medicine AI"}],"products":["Open-Medicine AI (OMAI) platform","withZeta.ai","ZetaOmics","RADR","LP-184 (zirdafulven)","LP-300","LP-284"],"companies":[{"name":"Lantern Pharma Inc.","ticker":"LTRN","relationship":"filer"},{"name":"Open-Medicine AI","relationship":"wholly owned subsidiary"},{"name":"Starlight Therapeutics","relationship":"CNS-focused subsidiary"},{"name":"Grand View Research","relationship":"market research source"},{"name":"IntuitionLabs","relationship":"industry tracker source"},{"name":"Securities.io","relationship":"media source"}],"dollarAmounts":[{"amount":"$2.9 billion","context":"estimated AI in drug discovery market in 2026 (analyst estimate)"},{"amount":"$13.8 billion","context":"projected AI in drug discovery market by 2033"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-17T12:20:51.196Z","global_importance":12,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"promotional-webinar-announcement","issuerAuthored":true,"commercialSubstance":"none-new-strategy-detail-only","retailNarrativeBoost":"AI drug discovery angle gives modest retail appeal"}},"durationMs":50876,"modelName":"glm-5.3-flash"}}